Immunotherapy for prostate cancer

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off

1998 • 989 citations

CTLA-4: new insights into its biological function and use in tumor immunotherapy

2002 • 923 citations

Dendritic Cells in Cancer Immunotherapy

2000 • 698 citations

Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

2000 • 627 citations

Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.

2001 • 597 citations

A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response

1999 • 515 citations

Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer

1989 • 511 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 491 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

2000 • 421 citations

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1993 • 411 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

2000 • 355 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy

2001 • 257 citations

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

2000 • 254 citations

Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

1999 • 253 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

2001 • 198 citations

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

1999 • 191 citations

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

1995 • 190 citations

Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial

2000 • 185 citations

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1995 • 185 citations

Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study

1997 • 177 citations

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1995 • 174 citations

Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

2000 • 164 citations

Follow-up evaluation of a phase II prostate cancer vaccine trial

1999 • 147 citations

Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

2000 • 145 citations

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

1999 • 145 citations

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

1999 • 144 citations

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

1996 • 132 citations

Phase I clinical trials.

1977 • 127 citations

Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.

1994 • 121 citations

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

1988 • 100 citations

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1997 • 99 citations

Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer

2002 • 97 citations

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

2002 • 96 citations

Dendritic Cell-Based Immunotherapy of Prostate Cancer

1998 • 95 citations

Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen

2002 • 92 citations

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

2001 • 87 citations

HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer

2001 • 75 citations

Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

1999 • 72 citations

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8⁺ T cells in prostate cancer patients

2002 • 72 citations

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

1998 • 67 citations

Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic Cancer

1987 • 58 citations

Tumor Associated Glycoprotein-72 is Highly Expressed in Prostatic Adenocarcinomas

1994 • 45 citations

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

2000 • 36 citations

Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.

1999 • 35 citations

Inhibition of human immunodeficiency virus type 1 replication by human interferons alpha, beta and gamma.

1993 • 11 citations

prostate stem cell antigen

2002 • 10 citations